ESC Premium Access

SGLT 2 inhibitor suppresses atrial fibrillation in the canine model of atrial fibrillation.

Presentation

About the speaker

Doctor Ryo Nishinarita

Nerima-Hikarigaoka Hospital, Tokyo (Japan)
0 follower

6 more presentations in this session

Four targeted therapies and less than four targeted therapies of underlying conditions against conventional therapy in atrial fibrillation - data from the RACE 3 study

Speaker: Miss B. Nguyen (Groningen, NL)

Thumbnail

Association of left atrial size with ischemic and bleeding risk scores in patients with non-valvular atrial fibrillation

Speaker: Doctor L. Enriquez Rodriguez (Soria, ES)

Thumbnail

How could non-vitamin k antagonist oral anticoagulants change clinical practice for stroke prevention and improve outcomes in patients with newly-diagnosed atrial fibrillation?

Speaker: Doctor T. Chao (Taipei, TW)

Thumbnail

High body mass index and outcomes of dual antithrombotic therapy with dabigatran and a P2Y12 inhibitor in patients with atrial fibrillation undergoing PCI: Results from RE-DUAL PCI

Speaker: Doctor R. De Caterina (Pisa, IT)

Thumbnail

Atrial fibrillation and risk of pulmonary arterial hypertension. Swedisk nationwide registry study

Speaker: Assistant Professor B. Hornestam (Gothenburg, SE)

Thumbnail

Access the full session

Atrial fibrillation - General 2

Speakers: Doctor R. Nishinarita, Miss B. Nguyen, Doctor L. Enriquez Rodriguez, Doctor T. Chao, Doctor R. De Caterina...
Thumbnail

About the event

Image

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

This platform is supported by

logo Novo Nordisk